Marrs Timothy Clive, Thompson John Paul
a Edentox Associates , Edenbridge, Kent , UK ;
b West Midlands Poisons Unit , Birmingham , UK ;
Clin Toxicol (Phila). 2016 Sep;54(8):609-14. doi: 10.1080/15563650.2016.1186804. Epub 2016 Jun 28.
Dicobalt edetate is one of a number of cobalt compounds that have been studied in the treatment of cyanide poisoning, their efficacy being based upon the fact that cyanide combines with cobalt to form relatively non-toxic complexes. Inorganic cobalt salts are quite toxic (cyanide and cobalt antagonise one another's toxicity) and complexes such as dicobalt edetate were studied with the aim of identifying compounds that were less acutely toxic, but which retained the antidotal properties of cobalt salts. The proprietary preparation, Kelocyanor™, contains free cobalt and glucose as well as dicobalt edetate.
The aim of this study was to evaluate the published evidence for the efficacy and adverse effects of dicobalt edetate.
A Pubmed search was undertaken for the period 1961-September 2015. The search terms were "dicobalt edetate", "cobalt edetate" and "Kelocyanor", which produced 24 relevant citations. A review of the references in four relevant books (L'intoxication cyanhydrique et son traitement, Clinical and Experimental Toxicology of Cyanides, Antidotes for Poisoning by Cyanide and Antidotes) produced three further relevant papers, making a total of 27 papers. Efficacy of dicobalt edetate: There is evidence from animal pharmacodynamic studies that dicobalt edetate is an effective cyanide antidote in experimental animals. Some 39 cases of human poisoning treated with dicobalt edetate have been reported, but in only nine cases were blood cyanide concentrations measured, although administration of dicobalt edetate procured survival in four of the seven patients with concentrations in the lethal range (>3.0 mg/L). It is unlikely that death in any of the adequately documented fatal cases was attributable to treatment failure with dicobalt edetate, as it is probable that they all had suffered anoxic brain damage before treatment could be initiated. Furthermore, in one case, acute gold toxicity contributed substantially to death. Adverse effects of dicobalt edetate: Adverse effects reported have included hypertension, tachycardia, nausea, retrosternal pain, sweating, palpebral, facial and laryngeal oedema, vomiting, urticaria and/or a feeling of impending doom. Such effects appear to be more prevalent where the antidote has been administered without evidence of substantial systemic poisoning or where other antidotes have been used which might have been expected also to combine with cyanide. Although the adverse effects observed were doubtless unpleasant, and some were severe, no fatal reactions were found.
Dicobalt edetate is an effective cyanide antidote when given to patients with systemic cyanide poisoning, but it has the potential to give rise to adverse reactions, particularly when administered in the absence of intoxication.
依地酸二钴是已被研究用于治疗氰化物中毒的多种钴化合物之一,其疗效基于氰化物与钴结合形成相对无毒的复合物这一事实。无机钴盐毒性相当大(氰化物和钴相互拮抗对方的毒性),对依地酸二钴等复合物进行了研究,目的是找出急性毒性较小但保留钴盐解毒特性的化合物。专利制剂Kelocyanor™含有游离钴、葡萄糖以及依地酸二钴。
本研究旨在评估已发表的关于依地酸二钴疗效和不良反应的证据。
对1961年至2015年9月期间进行了PubMed检索。检索词为“依地酸二钴”、“乙二胺四乙酸钴钠”和“Kelocyanor”,共产生24条相关引文。对四本相关书籍(《氰化氢中毒及其治疗》、《氰化物的临床与实验毒理学》、《氰化物中毒的解毒剂》和《解毒剂》)中的参考文献进行回顾,又得到另外3篇相关论文,共计27篇论文。依地酸二钴的疗效:动物药效学研究有证据表明依地酸二钴在实验动物中是一种有效的氰化物解毒剂。已报告约39例用依地酸二钴治疗的人类中毒病例,但仅9例测量了血氰浓度,尽管在7例血氰浓度处于致死范围(>3.0mg/L)的患者中,有4例因使用依地酸二钴而存活。在任何充分记录的致命病例中,死亡不太可能归因于依地酸二钴治疗失败,因为很可能他们在开始治疗前都已遭受缺氧性脑损伤。此外,在1例病例中,急性金中毒对死亡有很大影响。依地酸二钴的不良反应:报告的不良反应包括高血压、心动过速、恶心、胸骨后疼痛、出汗、眼睑、面部和喉部水肿、呕吐、荨麻疹和/或濒死感。在没有大量全身中毒证据的情况下使用解毒剂或使用了可能也会与氰化物结合的其他解毒剂时,这些不良反应似乎更常见。尽管观察到的不良反应无疑令人不适,有些还很严重,但未发现致命反应。
依地酸二钴用于全身氰化物中毒患者时是一种有效的氰化物解毒剂,但它有可能引起不良反应,尤其是在未中毒时使用。